Searching map area
Chronic myelogenous leukemia
? TBD
Type of blood cancer
Join to rate
Ratings
0
Nobody has rated this yet. Be the first!
Subclasses
1
Atypical chronic myeloid leukemia
Type of leukemia
Subject of
11
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
article by Simona Soverini et al published 15 December 2006 in Clinical Cancer Research
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
article by Gabriele Gugliotta et al published 26 May 2011 in Blood
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate
scientific article published on 10 August 2007
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
article
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
article
Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
scientific article published on 01 March 1994
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o
article by Simona Soverini et al published 20 June 2005 in Journal of Clinical Oncology
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib
scientific article published on 01 October 2011
Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison
scientific article published on 24 August 2018
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia
scientific article published on 01 August 2019
1 more
Lists
0
Join to rate

Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which a...

Instance of
class of disease
Subclass of
Myeloid leukemia
Disease
Wikidata